Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2220984 | 0.95 | HRH3 (0.71) | HRH3LMNADRD2DRD4DRD3 | |
| SCHEMBL2219924 | 0.92 | HRH3 (0.81) | HRH3LMNAKDM4EKMT2A | |
| SCHEMBL2220017 | 0.91 | HRH3 (0.74) | HRH3LMNAKDM4E | |
| SCHEMBL2216244 | 0.91 | HRH3 (0.79) | HRH3LMNAKDM4EKMT2A | |
| SCHEMBL2266831 | 0.89 | HRH3 (0.76) | HRH3LMNAKDM4EKMT2A | |
| SCHEMBL2214915 | 0.88 | HRH3 (0.83) | HRH3LMNAKDM4E | |
| SCHEMBL2218073 | 0.87 | HRH3 (0.98) | HRH3LMNA | |
| SCHEMBL2221039 | 0.87 | HRH3 (0.73) | HRH3LMNAKDM4EKMT2A | |
| SCHEMBL2218305 | 0.87 | HRH3 (0.70) | HRH3LMNAKDM4EKMT2A | |
| SCHEMBL2222687 | 0.87 | HRH3 (1.00) | HRH3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178062-A1 | INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-07-21 | — | — | US | claimed |
| CN-101679249-A | As histamine H 3The indoles of receptor modulators and benzothienyl compounds | JANSSEN PHARMACEUTICA NV | 2010-03-24 | — | — | CN | claimed |
| EP-2125720-A1 | INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2009-12-02 | — | — | EP | claimed |
| WO-2008109333-A1 | INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | claimed |
| US-20110178062-A1 | INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-07-21 | — | — | US | disclosed |
| US-20110178062-A1 | INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-07-21 | — | — | US | disclosed |
| US-20110178062-A1 | INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-07-21 | — | — | US | disclosed |
| CN-101679249-A | As histamine H 3The indoles of receptor modulators and benzothienyl compounds | JANSSEN PHARMACEUTICA NV | 2010-03-24 | — | — | CN | disclosed |
| WO-2008109333-A1 | INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178062-A1 | INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885LMNA 4860/4885DRD2 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.